Results 131 to 140 of about 25,220 (171)

Efficacy evaluation of the S-adenosylhomocysteine hydrolase inhibitor MSD-914 in rhesus macaques (Macaca Mulatta) challenged with Ebola virus by the intramuscular route. [PDF]

PLoS One
Johnston SC, Ginnetti AT, Twenhafel NA, Norris SLW, Chen S, Moore JL, Boyce CW, Frick OM, Dyer DN, Marsh DJ, Stevens SC, Knapp WF, Berrier KL, Wan H, Adam GC, Hartingh TJ, Esham HL, Fiallos JO, Blue EL, Sifford WB, Latty JD, Mills HL, Alli NA, Piper AE, Goodson AI, Meinig JM, Olsen DB, Lieberman LA, Panchal RG.   +28 more
europepmc   +1 more source

The Role of Posttranslational Modifications During Ebola Virus Infection. [PDF]

Viruses
Moreno-Contreras J, Peñaflor-Tellez Y, Rajsbaum R.   +2 more
europepmc   +1 more source

Interferons Inhibit Ebola Virus Infection of Human Keratinocytes. [PDF]

Viruses
Elliff J, Van Ert H, Sevcik K, Djurkovic MA, Rudd D, Gourronc F, Klingelhutz A, Shtanko O, Maury W.   +8 more
europepmc   +1 more source

A Rapid RT-RAA Assay for Visual Detection of Ebola Virus: Advancing Early Diagnosis in Resource-Limited Settings. [PDF]

Pathogens
Li Z, Dai J, Yang Z, Zhang M, Wang X, Ge C, Lu Y, Feng W, Song S, Zhang C, Cui H, Guo Z.   +11 more
europepmc   +1 more source

Discovery of three small-molecule inhibitors targeting <i>Ebolavirus</i> genome replication and transcription. [PDF]

J Gen Virol
Easton V, J McPhillie M, Barr J, Edwards T, Foster R, Fishwick C, Harris M.   +6 more
europepmc   +1 more source

Effect of the time of day for vaccination on the immune response to Ebola Virus Disease vaccines: A modeling study from PREVAC randomized trial. [PDF]

PLoS Negl Trop Dis
Kpetigo AD, Alexandre M, Camara A, Beavogui A, Doumbia S, Kieh M, Leigh B, Sow S, Wittkop L, Soutthiphong AA, Berry IM, Fleck S, Akoo P, Hamze B, Watson-Jones D, Kuhn JH, Greenwood B, Richert L, Yazdanpanah Y, Lévy Y, Thiébaut R, Prague M, PREVAC Study Team, Lhomme E.   +23 more
europepmc   +1 more source

Development of VP30-targeted nanoparticles using DPS4 fusion peptides for the inhibition of Ebola virus. [PDF]

J Nanobiotechnology
Wu F, Huang Y, Li R, Gao P, Lv P, Wu G, Ma Y, Ding Q, Zhong J, Su J, Xu W.   +10 more
europepmc   +1 more source

Fast-acting single-dose vesicular stomatitis virus-Sudan virus vaccine: a challenge study in macaques. [PDF]

Lancet Microbe
Fletcher P, O'Donnell KL, Feldmann F, Rhoderick JF, Clancy CS, Haase JA, Prator CA, Smith BJ, Gunn BM, Feldmann H, Marzi A.   +10 more
europepmc   +1 more source

Understanding the pathogenesis of uveitis in Ebola virus disease survivors: an observational cohort and cross-sectional study protocol for clinical, molecular virologic and immunologic characterisation. [PDF]

BMJ Open
Hartley CD, Linderman S, Fashina T, Ward L, Drews-Botsch C, Pratt C, Kuthyar S, Fernandes AF, Huang Y, Choo C, Nguyen N, Carag J, Morgan J, Kraft CS, Hewlett A, Brett-Major D, Schieffelin JS, Garry RF, Grant D, Justin GA, Conrady CD, Smith JR, Hayek BR, Balendra S, Acharya N, Doan T, Legand A, Formenty P, Zeng X, Conteh I, Vandy MJ, Harrison-Williams L, Mustapha J, Koroma Z, Wiley MR, Crozier I, Mwanza JC, Shantha JG, Ahmed R, Yeh S, SMILE and EVICT-VR Investigator Study Groups.   +40 more
europepmc   +1 more source

Antiviral Innate Responses Induced by VSV-EBOV Vaccination Contribute to Rapid Protection [PDF]

MBio, 2019
Ebola virus (EBOV) is the causative agent of Ebola virus disease (EVD), a deadly disease and major public health threat worldwide. A safe and highly efficacious vesicular stomatitis virus-based vaccine against EBOV is the only platform that has successfully completed phase III clinical trials and has been used in recent and ongoing outbreaks.
Ilhem Messaoudi, Heinz Feldmann, Andrea Marzi   +2 more
exaly   +4 more sources